Europe Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The European antibiotics and antimycotics market is projected to grow significantly, reaching approximately USD 19.87 billion by 2031, up from USD 13.48 billion in 2023, reflecting a compound annual growth rate (CAGR) of 5.0% during the forecast period.

Executive Summary and Market Analysis

The market is divided into several regions, including the UK, Germany, France, Italy, Spain, and the Rest of Europe. The growth of this market is primarily driven by the rising incidence of bacterial and fungal infections, alongside increasing government initiatives aimed at promoting the responsible use of antibiotics and antimycotics. Additionally, strategic actions such as product launches, regulatory approvals, and collaborations among key industry players are expected to further stimulate market growth in Europe.

Market Segmentation

The analysis of the European antibiotics and antimycotics market is categorized based on drug class, indication, route of administration, and distribution channel:

Drug Class: The market includes various drug classes such as penicillins, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillins held the largest market share.
Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTIs), septicemia, ear infections, gastrointestinal infections, and others. Respiratory infections accounted for the largest share in 2023.
Route of Administration: This includes oral, topical, and other methods, with oral administration being the most prevalent in 2023.
Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading in market share in 2023.

Market Outlook

Companies in the antibiotics and antimycotics sector are actively engaged in developing new products and enhancing existing ones, supported by funding for drug development and clinical trials. Recent developments in the market include:

In September 2024, F2G, a UK-based biopharmaceutical firm, secured USD 100 million to advance the late-stage development of olorofim, a novel oral antifungal treatment for invasive aspergillosis and other fungal infections.
In June 2024, the Global Antibiotic Research & Development Partnership (GARDP) collaborated with Bugworks Research Inc. to develop BWC0977, a broad-spectrum antibiotic targeting multidrug-resistant bacteria.
In June 2023, BioVersys became the first European company to receive funding from the AMR Action Fund for clinical trials aimed at combating bacterial resistance, with plans to launch 2-4 new antimicrobials by 2030.
In October 2022, CARB-X initiated funding rounds focused on critical health needs, including therapeutics for neonatal sepsis and gonorrhea, addressing urgent antimicrobial resistance issues.

These ongoing funding and research initiatives are expected to create significant growth opportunities in the antibiotics and antimycotics market in the coming years.

Country Insights

The market analysis by country reveals that Germany held the largest share in 2023. The growth in Germany is attributed to the high prevalence of bacterial and fungal infections and increased awareness of antimicrobial resistance (AMR). Reports indicate that over 500,000 individuals in Germany are affected by pneumonia annually, with a substantial number requiring hospitalization. Furthermore, the Robert Koch Institute reported that 400,000 to 600,000 patients experience hospital-acquired infections each year, leading to thousands of deaths.

The German government has implemented various initiatives to promote sustainable antibiotic use, including the German Antibiotic Resistance Strategy (DART 2030), which focuses on optimizing prescribing practices. Collaborative efforts among market players, such as the joint venture Aurobac launched by Boehringer Ingelheim, Evotec, and bioMerieux in June 2022, are also expected to enhance market growth.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Product Code: BMIRE00032105

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Europe Antibiotics and Antimycotics Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Infectious Diseases
- 4.1.2 Growing Awareness About Fungal Infections
4.2 Market Restraints
- 4.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
4.3 Market Opportunities
- 4.3.1 Ongoing Funding and Research & Development Initiatives
4.4 Future Trends
- 4.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
4.5 Impact of Drivers and Restraints:

5. Antibiotics and Antimycotics Market - Europe Analysis

5.1 Europe Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
5.2 Europe Antibiotics and Antimycotics Market Forecast Analysis

6. Europe Antibiotics and Antimycotics Market Analysis - by Drug Class

6.1 Penicillin
- 6.1.1 Overview
- 6.1.2 Penicillin: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Cephalosporines
- 6.2.1 Overview
- 6.2.2 Cephalosporines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.3 Carbapenems
- 6.3.1 Overview
- 6.3.2 Carbapenems: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.4 Macrolides
- 6.4.1 Overview
- 6.4.2 Macrolides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.5 Aminoglycosides
- 6.5.1 Overview
- 6.5.2 Aminoglycosides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.6 Quinolones
- 6.6.1 Overview
- 6.6.2 Quinolones: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.7 Sulfonamides
- 6.7.1 Overview
- 6.7.2 Sulfonamides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.8 Tetracyclines
- 6.8.1 Overview
- 6.8.2 Tetracyclines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.9 Azoles
- 6.9.1 Overview
- 6.9.2 Azoles: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.10 Others
- 6.10.1 Overview
- 6.10.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Antibiotics and Antimycotics Market Analysis - by Indication

7.1 Skin Infections
- 7.1.1 Overview
- 7.1.2 Skin Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Respiratory Infections
- 7.2.1 Overview
- 7.2.2 Respiratory Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Urinary Tract Infections (UTI)
- 7.3.1 Overview
- 7.3.2 Urinary Tract Infections (UTI): Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Septicemia
- 7.4.1 Overview
- 7.4.2 Septicemia: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Ear Infections
- 7.5.1 Overview
- 7.5.2 Ear Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Gastrointestinal Infections
- 7.6.1 Overview
- 7.6.2 Gastrointestinal Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Antibiotics and Antimycotics Market Analysis - by Route Of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Topical
- 8.2.1 Overview
- 8.2.2 Topical: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Antibiotics and Antimycotics Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Pharmacies
- 9.3.1 Overview
- 9.3.2 Online Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Antibiotics and Antimycotics Market - Country Analysis

10.1 Europe
- 10.1.1 Europe Antibiotics and Antimycotics Market Overview
- 10.1.2 Europe Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.1 Europe Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.2 Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.2.1 Germany: Europe Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.2.2 Germany: Europe Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.2.3 Germany: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.2.4 Germany: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.3 France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.3.1 France: Europe Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.3.2 France: Europe Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.3.3 France: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.3.4 France: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.4 Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.4.1 Spain: Europe Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.4.2 Spain: Europe Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.4.3 Spain: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.4.4 Spain: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.5 Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.5.1 Italy: Europe Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.5.2 Italy: Europe Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.5.3 Italy: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.5.4 Italy: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.6 United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.6.1 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.6.2 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.6.3 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.6.4 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.7 Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.7.1 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.7.2 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.7.3 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.7.4 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel

11. Antibiotics and Antimycotics Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Antibiotics and Antimycotics Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Novartis AG
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sanofi SA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Merck & Co Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 GSK Plc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Johnson & Johnson
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Cipla Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Bayer AG
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 AbbVie Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Astellas Pharma Inc
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms